Research Shows How Alzheimer's Plaques Lead to Loss of Nitric Oxide in Brain

The process by which the Alzheimer's disease interact with certain cellular proteins to inhibit normal signals that aids in the maintenance of blood flow to the brain, discovered by a researcher at the University of Pittsburgh School of Medicine.

Levels of nitric oxide (NO) - a signaling molecule that helps regulate blood flow, immune and neurological processes - are known to be low in the brains of people who have Alzheimer's disease, but the reason for that hasn't been clear, said study co-author Jeffrey S. Isenberg, associate professor, Division of Pulmonary, Allergy, and Critical Care Medicine, Pitt School of Medicine.

Alzheimer’s disease - Causes, Symptoms, Diagnosis, Stages, Types, Prevention, Prognosis & Treatment
Alzheimer's disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.

"Our research sheds light on how that loss of NO might happen, and reveals biochemical pathways that drug discoverers might be able to exploit to find new medicines for Alzheimer's," he said.

"There is evidence that suggests enhancing NO levels can protect neurons from degenerating and dying."

The researchers, led by first author Thomas Miller and senior author David D. Roberts, both of the Laboratory of Pathology in NIH's National Cancer Institute (NCI), found in mouse and human cell experiments that amyloid-beta, the main component of the plaques that accumulate on brain cells in Alzheimer's, binds to a cell surface receptor called CD36, which causes decreased activity of the enzyme soluble guanylate cyclase to reduce NO signaling. But that inhibitory effect required the presence of and interaction with CD47, another cell surface protein, indicating that additional steps in the pathway remain to be identified.

Caring for Alzheimers disease patients
Alzheimer's disease is a complex brain disorder that triggers the most common form of dementia. The slide show will show how patients need support and care as dementia progresses.

"It's possible that an agent that could block either CD36 or CD47 could slow the progress of neuronal degeneration in Alzheimer's by protecting the production of NO in the brain," Isenberg said.

"Importantly, we have already identified therapeutic agents that can interrupt the inhibitory signal induced by these interactions to maximize NO production, signaling and sensitivity."

Alzheimer's Disease may Not be Caused by High Mid-life Cholesterol Levels
A new, long-term study suggests that cholesterol level in mid-life may not be linked to later development of Alzheimer's disease.

The findings have been published in Public Library of Science One.

Source-ANI

Research Says Nicotine Could Play Role in Alzheimer's Disease Therapy
The debilitating side effects caused by a promising Alzheimer's drug can be eliminated by stimulating the brain's nicotine receptors, a team of scientists has revealed.